{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:06:16Z","timestamp":1794557176739,"version":"4.9.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1038\/s41584-022-00767-7","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T14:03:49Z","timestamp":1647957829000},"page":"301-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":201,"title":["Oral surveillance and JAK inhibitor safety: the theory of relativity"],"prefix":"10.1038","volume":"18","author":[{"given":"Kevin L.","family":"Winthrop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"767_CR1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).","journal-title":"N. Engl. J. Med."},{"key":"767_CR2","unstructured":"U.S. Food and Drug Administration. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and (2021)."},{"key":"767_CR3","unstructured":"U.S. Food and Drug Administration. Center for Drug Evaluation and Research: NDA 203,214 Tofacitinib for Rheumatoid Arthritis, Addendum to Primary Clinical Review. Edited by Department of Health and Human Services, 26 September 2012 edn. Silver Spring, MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203214Orig1s000Approv.pdf (2012)."},{"key":"767_CR4","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02092467 (2021)."},{"key":"767_CR5","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2665-9913(20)30032-1","volume":"2","author":"MC Genovese","year":"2020","unstructured":"Genovese, M. C. et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol. 2, e347\u2013e357 (2020).","journal-title":"Lancet Rheumatol."},{"key":"767_CR6","first-page":"1698","volume":"73","author":"KL Winthrop","year":"2021","unstructured":"Winthrop, K. L. et al. Integrated safety analysis update for filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 2.2 years [abstract]. Arthritis Rheumatol. 73, 1698 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"767_CR7","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","volume":"17","author":"V Strand","year":"2015","unstructured":"Strand, V. et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res. Ther. 17, 362 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"767_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2021.1934665","author":"I Parra-Izquierdo","year":"2021","unstructured":"Parra-Izquierdo, I. et al. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function. Platelets https:\/\/doi.org\/10.1080\/09537104.2021.1934665 (2021).","journal-title":"Platelets"},{"key":"767_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr2.11232","volume":"3","author":"JM Kremer","year":"2021","unstructured":"Kremer, J. M. et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. ACR Open Rheumatol. 3, 173\u2013184 (2021).","journal-title":"ACR Open Rheumatol."},{"key":"767_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395","volume":"6","author":"SB Cohen","year":"2020","unstructured":"Cohen, S. B. et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open 6, e001395 (2020).","journal-title":"RMD Open"},{"key":"767_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","volume":"81","author":"KL Winthrop","year":"2022","unstructured":"Winthrop, K. L. et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann. Rheum. Dis. 81, 184\u2013192 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"767_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/rheumatology\/keab294","volume":"61","author":"RJ Desai","year":"2021","unstructured":"Desai, R. J., Pawar, A., Khosrow-Khavar, F., Weinblatt, M. E. & Kim, S. C. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology 61, 121\u2013130 (2021).","journal-title":"Rheumatology"},{"key":"767_CR13","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","volume":"9","author":"VC Marconi","year":"2021","unstructured":"Marconi, V. C. et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 9, 1407\u20131418 (2021).","journal-title":"Lancet Respir. Med."},{"key":"767_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/art.41095","volume":"72","author":"JT Giles","year":"2020","unstructured":"Giles, J. T. et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 72, 31\u201340 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"767_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/acr.23875","volume":"72","author":"S Singh","year":"2020","unstructured":"Singh, S. et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res. 72, 561\u2013576 (2020).","journal-title":"Arthritis Care Res."},{"key":"767_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221915","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar, F., Kim, S. C., Lee, H., Lee, S. B. & Desai, R. J. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221915 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"767_CR17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2020","unstructured":"Cohen, S. B. et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann. Rheum. Dis. 80, 304\u2013311 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"767_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/ibd\/izab056","volume":"2","author":"BE Sands","year":"2022","unstructured":"Sands, B. E. et al. Tofacitinib for the treatment of ulcerative colitis: analysis of nonmelanoma skin cancer rates from the Ulcerative Colitis Clinical Program. Inflamm. Bowel Dis. 2, 234\u2013245 (2022).","journal-title":"Inflamm. Bowel Dis."},{"key":"767_CR19","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41423-019-0320-3","volume":"17","author":"G Nocturne","year":"2020","unstructured":"Nocturne, G., Pascaud, J., Ly, B., Tahmasebi, F. & Mariette, X. JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis. Cell. Mol. Immunol. 17, 552\u2013553 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"767_CR20","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Bhala, N. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382, 769\u2013779 (2013).","journal-title":"Lancet"},{"key":"767_CR21","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E. & Beenhouwer, D. O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38, 1261\u20131265 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"767_CR22","unstructured":"European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7\u201310 June 2021 https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-june-2021 (2021)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00767-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00767-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00767-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T22:45:55Z","timestamp":1733957155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00767-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["767"],"URL":"https:\/\/doi.org\/10.1038\/s41584-022-00767-7","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"assertion":[{"value":"17 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.L.W. declares that he has acted as a consultant for AbbVie, Union AstraZeneca, Bristol Myers Squibb (BMS), Chimique Belge (UCB), Eli Lilly & Company, Galapagos, Gilead, GlaxoSmithKline, Novartis, Pfizer, Regeneron, Roche and Sanofi, and has received research funding from Bristol Myers Squibb and Pfizer. S.B.C. declares that he has acted as a consultant for and received research funding from AbbVie, Amgen, Gilead, Lilly and Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}